Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Immunovant, Inc.
The company has ramped up a broad R&D program for the FcRn inhibitor in 11 autoantibody-driven disease areas.
Public Company Edition: This year is just six initial public offerings away from matching 2020’s record-breaking total of 86 biopharma IPOs in the US. Also, Idorsia raised $662.5m through the sale of convertible bonds and Cytokinetics closed a $316.3m follow-on offering.
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m.
- Other Names / Subsidiaries
- Health Sciences Acquisitions Corporation